Martin Kulander

Martin Kulander has held a variety of roles in the life sciences industry. In 2021, they joined Transition Bio, Inc. as Chief Operating Officer. From 2018 to 2021, they were with AstraZeneca, where they held the roles of Senior Director/Executive Director of Oncology R&D Strategy, Senior Director of Tumour Strategy, and Director of Tumour Strategy. In 2016, they joined Malin Corporation plc as a Venture Capital Investor. Prior to that, they were a Consultant at TRINITY from 2012.

Martin Kulander attended Dartmouth College, where they earned a Bachelor of Arts (B.A.) in Chinese Language and Literature, with a minor in Biology.